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Exploring Acupuncture through the Spectrum of Public Health Research
Background: Studying the mechanisms and effects of acupuncture in Europe and Western countries has largely depended on
biomedical research paradigms (e.g. in vitro experiments, randomized clinical trials). These approaches have drawbacks as
well as advantages. This presentation will focus on clinical and public health-based research designs, including two of the
presenter’s studies (randomized clinical trial of acupressure for neonatal abstinence syndrome and a health economics
evaluation of price elasticity of acupuncture, Chinese herbal medicine, and Shiatsu) and offer critiques of each prototype.
Thesis: Our research can and must honor both the tradition of Chinese/Asian Medicine as well as the tradition of biomedical
science. This requires innovative thinking, working with multi-disciplinary teams, and dedicated scholarship.
The following types of study designs can be used to investigate clinical, patient-centered, and utilization aspects of acu-
puncture: descriptive study (correlation, case reports, cross-sectional surveys); cohort approaches (longitudinal, case-
control); assessments of intervention effects (randomized clinical trial); and health services research approaches (patient
demographics, satisfaction with care, patient perception of care, and economics including cost-effectiveness). This pre-
sentation will compare and contrast these types of approaches, as well as illustrate how two of these paradigms have been
operationalized by a public health researcher.
Discussion: Each type of study approach has inherent advantages and disadvantages. The process of study design involves
a yin/yang process of examining and striving to balance these intrinsic characteristics. Because of acupuncturists’ under-
standing of the comprehensive systems’ nature of Traditional Chinese/Asian Medicine, it is imperative that acupuncturists
play major roles in designing studies, and not merely conducting them.
Sommers E. Exploring Acupuncture through the Spectrum of Public Health Research. In proceedings from the International
Scientific Acupuncture and Meridian Symposium, Oct 5-Oct 7, 2012; Sydney, AustraliaChinese Herbal Medicine for Constipation Predominant Irritable Bowel Syndrome
Context: Irritable bowel syndrome (IBS) is a common functional bowel disorder for which there is no reliable medical
treatment. Over 10% of Australians have IBS. It is the most common chronic medical disorder of the digestive tract, and
around 40% of all IBS patients have constipation predominant IBS (C-IBS). C-IBS has multiple symptoms, including abdominal
pain, bloating, constipation and changed bowel habits.
Objective: To evaluate the efficacy and monitor the safety of a standardised preparation of Chinese herbal medicine (CHM)
for the treatment of C-IBS and alterations in psychosocial status. The CHM formulation is designed to address the multiple
symptom nature of C-IBS.
Design:A two-armrandomised,double-blind,placebo-controlled,multi-centreclinical trial conductedduring2009through2012.
Setting: Patients were recruited through gastroenterologists, general practitioners (GP) and advertising. Thirteen study
sites were established including the Royal North Shore Hospital, University of Western Sydney, and 9 private practices of
gastroenterologists, GP’s or Chinese medicine practitioners.pISSN 2005-2901 eISSN 2093-8152
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Conference abstracts 61Patients: A total of 127 patients met the inclusion criteria including a gastroenterologist/GP referral process based on the
Rome III criteria, a standard for diagnosis of C-IBS.
Intervention: Patients were randomly allocated to either the treatment group; receiving a standard 7 ingredient CHM
formulation extracted and encapsulated (nZ 63), or placebo (nZ 64). Patients received 5 capsules twice daily for 8 weeks
with an 8 week follow up and were evaluated regularly. Chemical definition and standardisation of the formula were
completed prior to commencement of the trial and stability testing was performed throughout the study. Participants,
referring doctors, study gastroenterologists, site researchers and principal investigators were all blinded to treatment
group.
Main outcome measures: The primary outcome measure consists of a patient reported global symptom improvement.
Secondary outcome measures include visual analogue scales related to each symptom of IBS (pain/discomfort, bloating,
constipation and diarrhoea). Quality of life was assessed using the validated IBSQoL and the SF36. Degree of interference
with life, Bristol stool form scale (reflecting bowel transit times), full blood count, urea, creatinine, liver function tests,
success of blinding of treatment (self report scale), dietary changes (fibre intake only), compliance with trial medication
and health care resources usage for IBS were also undertaken incorporating the WPAI. Comprehensive psychosocial
assessment for personality style was measured using the NEO-FFI, depressive and anxiety symptoms were recorded using the
DASS.
Results: Preliminary results report patients in the active treatment group compared with the placebo group had a statis-
tically significant improvement in the primary outcome of adequate relief of symptoms after 8 weeks intervention
(pZ0.015) and overall satisfaction with improved bowel habits compared to placebo (p<0.001). Monitoring of the Bristol
Stool Scale also demonstrated a statistically and clinically significant improvement in stool consistency at the end of the
trial (p<0.001). However, the preliminary data showed no statistically significant improvement in abdominal pain.
Conclusion: The preliminary results suggest a standard CHM formulation may offer improvement in bowel satisfaction and
stool consistency in C-IBS.
Bensoussan A, Kellow J, Bourchier S. Chinese herbal medicine for constipation predominant irritable bowel syndrome, In
proceedings from the International Scientific Acupuncture and Meridian Symposium, Oct 5-Oct 7, 2012; Sydney, AustraliaChinese Herbal Medicine for Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation that is not fully reversible.
COPD is a major cause of morbidity and mortality and is the 4th leading cause of death worldwide. Current treatments
produce only modest increases in lung function and they are associated with a range of adverse effects. New therapies are
being developed. However, there is a critical need to provide effective symptomatic relief and improve the quality of life of
sufferers. There has been increasing interest in complementary medicines for the management of COPD, in particular,
herbal medicines.
Recent systematic reviews showed herbal medicine have promising results for moderating the immune response as well
evidence of lung function and quality of life improvement. One of the most promising herbs is Panax ginseng. It is tradi-
tionally used for the treatment of breathlessness, debilitation and reduced physical and functional capacities due to chronic
illness. Ginseng has an excellent safety profile. Clinical studies demonstrated that it was well tolerated by patients, with
rare occurrences of minor gastrointestinal discomfort such as diarrhoea.
A clinical trial is underway investigating the potential efficacy and safety of Panax ginseng for people with moderate COPD.
Outcome measures include quality of life and lung function. The multi-centre randomised, double-blind, placebo-controlled
clinical trial is being conducted in four Melbourne hospitals. Findings from this study may lead to new therapeutic devel-
opment for a range of chronic inflammatory diseases, particularly chronic respiratory diseases. www.rmit.edu.au/
healthsciences
Zhang T, Shergis J, Thien F, Wornop C, An X, May B, Xue C. Chinese herbal medicine for chronic obstructive pulmonary
disease (COPD). In proceedings from the International Scientific Acupuncture and Meridian Symposium, Oct 5-Oct 7, 2012;
Sydney, AustraliaSystematic Review on DENGZHANHUA Intravenous Injection for Acute Cerebral
Infarction - Focusing on the Chinese Medical Journals
Objectives: Dengzhanhua(Breviscapine) intravenous injection is widely used for the treatment of acute cerebral infarction
patients in China. The systematic review on intravenous injections can make sporadic reports easy to conclude the effects
and benefits.
Methods: The study was performed through searching the database of CNKI (website: www.cnki.com) for the Chinese
papers on intravenous injections. Inclusion criteria were only Chinese articles and the publication periods limited from 1979
62 Conference abstractsto 2011. Objects were human, not animals, and the duration from the onset of the cerebral infarction to treatment were
within 7 days. The key words were ‘cerebral infarction (脑梗塞 or 脑梗死) )’ and ‘Dengzhanhua (灯盏花, DZH)’. Ordinary
western medicine treatment including anti-hypertensive drugs or glucose-regulation drugs were equally allocated both
treatment group (DZH group) and control group (thrombolytic group). So outcomes were measured as total neurological
improvement efficacy between DZHþwestern medicine treatment group (DZH group) versus anti-platelet treatment or
thrombolytic treatmentþwestern medicine treatment (thrombolytic group).
Results: A total of 574 papers were searched and after inclusion/exclusion criteria only 16 papers were left. 8 papers were
extracted through discriminating a homogeneous neurological improvement efficacy method. Analyzing the total cases and
efficacies, the efficacy of DZH group was 75.7%, and that of thrombolytic group was 60.4%.
Conclusion: This evidence suggests that DZH treatment via intravenous injection may be useful as well as thrombolytic or
anti-platelet treatment for treating acute cerebral infarction. For the lack of adequate scaling method of the neurological
improvement, however, we recommend that further research designed randomized-clinical trial and the multi-variable
statistical method include risk ratio would be required in this area.
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